Article Text

Download PDFPDF
179 Early real-world experience of ocrelizumab in MS
  1. Katharine Harding1,
  2. Gillian Ingram2,
  3. Emma Horton1,
  4. Helen Owen2,
  5. Fady Joseph1,
  6. Owen Pearson2
  1. 1Royal Gwent Hospital
  2. 2Morriston Hospital


Background Ocrelizumab was recently licensed for use in relapsing-remitting multiple sclerosis (MS). We present our clinical experience of ocrelizumab treatment for MS in two specialist centres in south Wales.

Methods All patients with MS treated with ocrelizumab in Newport and Swansea between 01/08/2018 and 31/12/2018 were included. Sex ratio, age at MS onset and baseline EDSS score were calculated. Data was collated on indication for treatment and adverse effects, and data on previous DMT sequencing will be discussed.

Results Eighty-one patients (82% female) were treated in total. Mean age at onset was 32.4 years, and mean age at ocrelizumab treatment was 42.8 years. Baseline EDSS was <4.0 in 45 (55%), 4.0–6.0 in 24 (30%), and 6.0–6.5 in 12 (15%). The commonest indication was first-line treatment for active disease (n=26, 32%), followed by side effects from other disease-modifying treatment (n=20, 25%), and high JCV titre on natalizumab (n=15, 19%). Sixty-two patients (77%) had no adverse effects. Eleven patients (14%) had infections. Three patients (4%) had infusion reactions. One patient had an allergic reaction to ocrelizumab and discontinued treatment. There were no cases of PML.

Discussion Ocrelizumab has been safe and well-tolerated in our cohort. Our study illustrates the value of real-world clinical data in MS.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.